The combination significantly improved tumor growth inhibition, as shown by the graphs of tumor volume and tumor weight (Figure 4D,E); in addition, it led to a higher survival rate than that of the vehicle or ATO, or anti-PD-L1 antibody treatment alone (Figure 4F). This evidence concerns the gene CD274 and neoplasm.